Connect your AI

Organon OGN Investing Cash Flow

Investing Cash Flow at other companies

PfizerPFE

$785M-76.0%

AmgenAMGN

-$716M-60.2%

The Cooper Companies, Inc.COO

-$90M-13.6%

BiogenBIIB

-$209.5M-343%

AbbVieABBV

-$574M+21.9%

Amneal Pharmaceuticals, Inc.AMRX

-$21.71M-22.0%

Other financials

Income statement

Revenue$1.5B-3.5%

Gross profit$783.0M-6.9%

Net income$146.0M+67.8%

EPS (diluted)$0.55+66.7%

Balance sheet

Cash & equivalents$1.1B+104%

Total debt$8.6B-4.3%

Total equity$903.0M+66.6%

Total assets$13.0B-1.2%

Cash flow

Operating cash flow$225.0M+200%

CapEx$37.0M+15.6%

Free cash flow$188.0M+337%

Valuation

Market cap$3.53B-59.4%

Profitability

Gross margin52.8%-4.4pp

Net margin8%-12.3pp

FCF margin11.1%-1.3pp

Returns & leverage

Return on equity71.6%—

Debt / equity9.5×-7.0×

Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Organon's investing cash flow?: Organon (OGN) reported investing cash flow of $386M in Q1 2026.
How has Organon's investing cash flow changed year-over-year?: Organon's investing cash flow increased by 324.4% year-over-year, from -$172M to $386M.
What is the long-term trend for Organon's investing cash flow?: Over 4 years (2021 to 2025), Organon's investing cash flow has grown at a -5.1% compound annual growth rate (CAGR), from -$481M to -$390M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.